Mitomycin-C bladder instillation syringe kit
US11554095B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 24, 2020 |
| Grant date | Jan 17, 2023 |
| Priority date | — |
| Expiry date | Nov 30, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides compositions, methods, and devices for use in delivering Mitomycin-C(MMC), an antineoplastic chemotherapy drug often used for bladder instillations to treat bladder cancer, which degrades in both acidic and alkaline environments. The disclosure provides a solution of buffered MMC (or a different drug) in 50% propylene glycol that maintains a pH from 7.0 to 8.0 when introduced into acidic solutions (pH of 5.0) and is stable when stored at 2-8° C. for greater than 134 days. This formulation can be produced in an FDA registered 503B Outsourcing facility in a pre-filled, ready-to-administer syringe kit with pre-attached closed system transfer device and accessories required for bladder instillation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.